NL-OMON40282已完成2 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF 3-MONTH SUBCUTANEOUS REGN1033 TREATMENT IN PATIENTS WITH SARCOPENIA - R1033-SRC-1239
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Men and women aged 70 years and older;2. Are capable, in the investigator's opinion, to complete the study per protocol and have no significant health issues or conditions (including but not limited to severe arthritis of the major lower extremity joints and symptom-limited ambulation) that would impact the capability to get an accurate measurement of study endpoints;3. Appendicular lean mass relative to height squared: <=7.23 kg/m² (men); <=5.67 kg/m² (women);4. 4M gait speed <1.0 m/s (>4s to travel 4 meters at normal walking pace);5. BMI between 18.5 kg/m² and 37 kg/m², inclusive;6. Ability to follow a physical activity and walking program (involving activity such as walking starting with 5 to 10 minutes on most days of the week, and progressing to 30 minutes on most days of the week).;7. Willing and able to comply with clinic visits and study-related procedures;8. Provide signed informed consent;9. Able to understand and complete study-related questionnaires
排除标准
- •1. Hospitalization or immobilization with a duration of >48 hours within the month prior to screening;2. Having had a surgical procedure within 1 month prior to screening that required general anesthesia and was associated with loss of ambulation for at least 3 days, or a planned surgical procedure requiring general anesthesia within the next 6 months.;3. Participate in muscle strengthening training involving major muscle groups of arms and legs for at least 20 minutes 3 times per week AND regular exercise consisting of an average of 30 minutes per day or more of at least moderate physical activity which increases heart rate and breathing rate. ;4. Chronic medications introduced within 2 weeks prior to screening;5. Weight loss of >10% body weight within 6 months prior to screening;6. Respiratory disease (eg, severe chronic obstructive pulmonary disease) that requires oxygen treatment;7. Cancer requiring treatment currently or in the past 3 years (except primary nonmelanoma skin cancer or in situ cervical cancer), or any weight loss attributed to cancer within the last year (per the investigator's assessment);8. Neurological conditions that are causing impaired muscle function or mobility (may include stroke with residual paresis, paralysis, neuropathy, Parkinson disease, or multiple sclerosis);9. MMSE score of <24;10. Active or inadequately treated Major Depressive Disorder within 3 months prior to screening;11. Cardiovascular conditions such as New York Heart Association class III or IV heart failure, cardiomyopathy, intermittent claudication, myocardial infarction, or acute coronary syndrome within 6 months prior to screening; symptomatic ventricular cardiac arrhythmia (note: sinus dysrhythmia, asymptomatic block or well controlled atrial fibrillation with normal resting ventricular rate are not exclusion criteria);12. Abnormal echocardiogram findings at screening that are clinically significant, which may include but are not limited to:;- Cardiomyopathy;- Left ventricular ejection fraction <50%;- Moderate or severe diastolic dysfunction, grade II/III;- Aortic stenosis;- Valvular disease with hemodynamic significance;- Left ventricular wall thickness >=1.4 cm (men) and >=1.3 cm (women);13. Uncontrolled diabetes defined as hemoglobin A1C (HbA1C) >10% at screening (1 retest allowed);14. Diastolic blood pressure >100 mm Hg or systolic blood pressure >180 mm Hg (average of 2 readings);15. Alanine aminotransferase (ALT) >3x the upper limit of normal (1 retest allowed);16. Reduced renal function defined as estimated glomerular filtration rate <30 mL/min/1.73 m² (1 retest allowed);17. Creatine phosphokinase >5 x the upper limit of normal (1 repeat lab is allowed);18. Use of any prescription or over-the-counter agents known to influence muscle mass or performance within 1 year prior to screening. These may include but are not limited to;anabolic steroids, insulin-like growth factor-1 (IGF-1), growth hormone (GH), replacement androgen therapy, and anti-androgen therapy.;19. Participation in any clinical trial of small molecule drugs within 30 days prior to screening or biologics within 3 months prior to screening;20. Participation within 6 months prior to screening in clinical trials of interventions that are intended to influence muscle mass or performance;21. History of human immunodeficiency virus infection;22. Positive test for hepatitis B surface antigen and/or hepatitis C antibody at the screening visit;23.
研究者
相似试验
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SUPERIORITY OF CRX-102 OVER EACH OF ITS COMPONENTS WHEN GIVEN TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)RHEUMATOID ARTHRITIS (RA)MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2007-003069-42-GBCombinatoRx, Incorporated616
进行中（未招募）
1 期
A blind (not knowing which treatment to receive), placebo-controlled (with chance to receive sugar pill) study to evaluate whether Brivaracetam can be used treating partial onset seizures in patients with epilepsy (= 16 to 80 years old)Partial onset seizuresMedDRA version: 14.0 Level: PT Classification code 10061334 Term: Partial seizures System Organ Class: 10029205 - Nervous system disordersEUCTR2010-019361-28-GBCB BioSciences Inc. A Member of the UCB Group of Companies768
进行中（未招募）
不适用
A blind (not knowing which treatment to receive), placebo-controlled (with chance to receive sugar pill) study to evaluate whether brivaracetam can be used treating partial onset seizures in patients with epilepsy (= 16 to 80 years old)Partial onset seizuresMedDRA version: 14.1Level: PTClassification code 10061334Term: Partial seizuresSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-019361-28-NLCB Biosciences Inc.900
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SUPERIORITY OF CRX-102 OVER EACH OF ITS COMPONENTS WHEN GIVEN TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)RHEUMATOID ARTHRITIS (RA)MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2007-003069-42-LTCombinatoRx, Incorporated616
进行中（未招募）
1 期
Study to evaluate effect of MIN-102 compared to Placebo after 96 weeks of randomized, double-blind Treatment followed by open-label extension study to evaluate effect of long term treatment with MIN-102 on the progression of adrenomyeloneuropathy (AMN) in male patientsEUCTR2017-000748-16-NLMinoryx Therapeutics S.L.105